MIRA INFORM REPORT

 

 

Report No. :

331421

Report Date :

17.07.2015

 

IDENTIFICATION DETAILS

 

Name :

TUTTNAUER LTD.

 

 

Formerly Known As :

NEEV TUTTNAUER & SON LTD

 

 

Registered Office :

Har Tuv B, Hesegim Industrial Park, Mateh Yehuda Regional Council

 

 

Country :

Israel

 

 

Financials (as on) :

30.09.2009

 

 

Year of Establishment :

1925

 

 

Legal Form :

Private Limited Company

 

 

Line of Business :

Designers, manufacturers, importers, marketers and exporters of hospital and laboratory equipment, scientific equipment for hospitals and laboratories, specializing in autoclaves for the fields of sterilization, and infection control.

 

 

No. of Employees :

400 Employees.

 

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

 

Status :

Satisfactory

 

 

Payment Behaviour :

No Complaints

 

 

Litigation :

Clear

 

 

NOTES:

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

 

ECGC Country Risk Classification List – March 31, 2015

 

Country Name

Previous Rating

(31.12.2014)

Current Rating

(31.03.2015)

Israel

B1

B1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

ISRAEL - ECONOMIC OVERVIEW

 

Israel has a technologically advanced market economy. Cut diamonds, high-technology equipment, and pharmaceuticals are among the leading exports. Its major imports include crude oil, grains, raw materials, and military equipment. Israel usually posts sizable trade deficits, which are covered by tourism and other service exports, as well as significant foreign investment inflows. Between 2004 and 2013, growth averaged nearly 5% per year, led by exports. The global financial crisis of 2008-09 spurred a brief recession in Israel, but the country entered the crisis with solid fundamentals, following years of prudent fiscal policy and a resilient banking sector. Israel's economy also has weathered the Arab Spring because strong trade ties outside the Middle East have insulated the economy from spillover effects. Slowing demand domestically and internationally and reduced investment due to uncertainties caused by the Gaza conflict in summer 2014 have reduced GDP growth to about 2% during 2014. Natural gas fields discovered off Israel's coast since 2009 have brightened Israel's energy security outlook. The Tamar and Leviathan fields were some of the world's largest offshore natural gas finds this past decade. The massive Leviathan field is expected to come online no sooner than 2017, but production from Tamar provided a one percentage point boost to Israel's GDP in 2013 and a 0.5% boost in 2014. In mid-2011, public protests arose around income inequality and rising housing and commodity prices. Israel's income inequality and poverty rates are among the highest of OECD countries and there is a broad perception among the public that a small number of "tycoons" have a cartel-like grip over the major parts of the economy. The government formed committees and has started splitting up the oligopolies to address some of the grievances but has maintained that it will not engage in deficit spending to satisfy populist demands. Over the long term, Israel faces structural issues, including low labor participation rates for its fastest growing social segments - the ultra-orthodox and Arab-Israeli communities. Also, Israel's progressive, globally competitive, knowledge-based technology sector employs only 9% of the workforce, with the rest employed in manufacturing and services - sectors which face downward wage pressures from global competition.

 

Source : CIA

 

 

Company Name and address

 

TUTTNAUER LTD.

Telephone    972 2 990 46 11; 990 46 00

Fax              972 2 990 47 00

Email:          info@tuttnauer.com

 

Physical Address

Har Tuv B, Hesegim Industrial Park

MATEH YEHUDA REGIONAL COUNCIL ISRAEL

 

Mailing Address

P.O. Box 170

BEIT SHEMSH 9910101 ISRAEL

 

 

HISTORY & LEGAL FORMATION

 

Originally established as a non-registered business in 1950 by Late Zeev Tuttnauer, grandfather of Ran Tuttnauer, continuing activities he founded in 1925 in the framework of his work at the Hebrew University.

 

Converted into a private limited company, under the style ZEEV TUTTNAUER & SON LTD., incorporated as per file No. 51-022893-5 on the 29.01.1960.

 

In November 1993 published a prospectus offering shares to the public, raising a sum of NIS 45 million, according to a company value of US$ 60 million.

In parallel, converted into a public limited company and registered as such as per file No. 52-004002-3 on the 06.10.1993.

 

On 31.12.2009, following a successful tender offer to the public, subject's shares were de-listed from trade, and subject re-converted to a private limited company (keeping the same latter registration number).

 

 

SHARE CAPITAL

 

Authorized share capital NIS 10,000,000.00, divided into -

10,000,000 ordinary shares of NIS 1.00 each, of which 7,331,703 shares amounting to NIS 7,331,703.00 were issued.

 

 

SHAREHOLDERS

 

Subject is fully owned by Tuttnauer family (directly, via a held company Y.R.H.T. (1995) LTD. and via a trust company), headed by Mrs. Hava Tuttnauer and Ran Tuttnauer.

 

 

DIRECTORS

 

1.      Ran Tuttnauer son of Mrs. Hava and Yehoshua Tuttnauer, General Manager, born 1961,

2.      Mrs. Hava Tuttnauer, wife of the Late Yehoshua Tuttnauer (son of Zeev Tuttnauer).

 

 

BUSINESS

 

Designers, manufacturers, importers, marketers and exporters of hospital and laboratory equipment, scientific equipment for hospitals and laboratories, specializing in autoclaves for the fields of sterilization, and infection control.

 

In the autoclave niche, subject produces “table autoclaves” for clinics, dentists and such, as well as “industrial autoclaves” for large research institutes, hospitals, food factories and pharmaceutical industries.

 

Also importers and marketers of medical equipment and computer peripherals.

 

Local agents of NETZCH-BELIMED.

 

Subject products are exported all over the world through subsidiaries in Europe and the U.S.A. and through local agents in the Far East, Australia and South America. According to our, export volume comprises some 90% of sales, mostly U.S.A.

Among clients are hospitals and medical institutions, including universities, e.g. Chicago University, Cornell University, etc.

 

Among local suppliers: MASHAF TECHNICAL SUPPLIES, INTERNATIONAL PROCESS CONTROLS CO., etc.

 

Operating from owned premises, offices and plant, on an area of 30,000 sq. meters (on which built area of 13,000 sq. meters), in the Har Tuv B'1, Hesegim Industrial Park, in the Regional Council Mateh Yehuda (near Beit Shemesh). Also operating from branches in the USA (owned premises on an area of 4,000 sq. meters) and Europe - Netherlands (rented premises on an area of 300 sq. meters).

 

Having some 400 employees.

 

 

MEANS

 

Consolidated B/S shows (last published and last obtainable):

 

                                                                                                NIS (thousands)

                                                                                    31.12.2008            30.09.2009

ASSETS

Current assets:

      Cash and cash equivalents                                               30,290                  43,578

      Customers                                                                       45,730                  36,181

      Other debtors                                                                    6,920                    5,798

      Stock                                                                             _74,017                 _65,393

                                                                                           156,957                 150,950

Non-current assets:

       Prepaid expenses and deferred taxes                                8,650                    9,512

       Fixed assets (net)                                                          _67,721                 _66,306

                                                                                           _76,371                 _75,818

                                                                                           233,328                 226,768

                                                                                         =======              =======

 

LIABILITIES

Current liabilities                                                                     57,703                  50,027

Long term liabilities                                                                27,394                  25,437

Equity                                                                                  148,321                 151,304

                                                                                           233,328                 226,768

                                                                                         =======              =======

 

 

Stock was valued at US$ 25,000,000 in the end of 2011.

 

Later and other financial data not forthcoming.

 

Prior the purchase offer, subject was valued at NIS 171 million, and the offer for share purchase was at circa 50% premium.

 

Subject is an “Approved Enterprise” and as such enjoys tax benefits and State incentives.

In January 2000 the Israeli Investment Center (IIC) approved a US$ 690,000 investment plan for the expanding subject’s plant (then it was in Jerusalem).

In June 2002 IIC approved subject’s plan to expand its plant in Beit Shemesh, for a sum of US$ 2.5 million.

 

 

There are 9 charges for unlimited amounts registered on the company's assets (financial assets, fixed assets and equipment), in favor of Bank Leumi Le'Israel Ltd. and The First International Bank of Israel Ltd. (last charge placed June 2014).

 

 

REVENUES

                                                                                 Consolidated Statement of Income

                                                                                                   NIS (thousands)

                                                                                                Year ended 31.12

                                                                                         2006              2007                2008

Sales                                                                              209,905           233,219          213,008

 

Gross profit                                                                      87,189             80,704            72,263

 

Operating income                                                              21,044             19,096            11,810

 

Profit before tax on income                                               18,797             17,930              8,309

 

Net income                                                                       18,235             17,979              7,609

                                                                                      ======           ======          ======

 

 

According to subject's last published financial statements:

Consolidated first 3 quarters of 2009 sales NIS 149,688,000 (a 3.8% decrease compared to the parallel period in 2008), making a gross profit of
NIS 52,401,000, an operating income of NIS 10,253,000 and a net profit of
NIS 7,986,000.

Subject's CFO updated us on subject's (solo) sales data since then (in US$):

2009 (whole year) sales were around US$ 57,000,000, 90% of which were for export.

2010 sales were US$ 55,000,000, 90% of which were for export.

2011 sales were US$ 60,000,000, 90% of which were for export.

2012 sales not forthcoming.

2013 sales reported to be circa NIS 250,000,000.

2014 sales reported to be circa NIS 250,000,000.

 

 

OTHER COMPANIES

 

Y.R.H.T. (1995) LTD., 100%,

TUTTNAUER EUROPE B.V., 100%, Netherlands, marketing company,

TUTTNAUER U.S.A CO. LTD., 100%, USA, marketing company,

EYTAN ENGINEERING & SERVICES (OF THE TUTTNAUER GROUP) LTD., 90%, importers and marketers of medical, laboratory and Uninterruptible Power Supply (UPS) equipment.

 

Also owned by the Tuttnauer Family CT TECHNOLOGIES LTD., 50%, developers of control systems for subject’s products.

Y.R.H.T. (1995) LTD.

 

 

BANKERS

 

The First International Bank of Israel Ltd., Kiryat Moshe Branch (No. 114), Jerusalem, account No. 187100.

Bank Leumi Le’Israel Ltd., Main Branch (No. 901), Jerusalem, account No. 356000/11.

A check with the Central Banks' database did not reveal any negative information regarding subject's a/m accounts.

 

 


CHARACTER AND REPUTATION

 

Nothing unfavorable learned.

 

Despite our efforts, we were unable to speak with subject's head accountant, who told us he is very busy.

 

Subject is certified for ISO 9001:2000, CE, TUV, ASME, UC, EN601 and other international standards.

 

Subject is a very veteran business, among the leading in its field, and claims to be one of the leading 3 companies in the world in the field of infection control, and having 80% market share in Israel in the autoclave field (2011).

 

Ran Tuttnauer served during 2009-2010 as the Chairman of the Labor Committee of the Manufactures Association of Israel.

 

In March 2002, subject acquired a sterilization technology from MICROLASER TECHNOLOGY, for a sum of US$ 100,000.

 

In 2001, subject leased (for ages) from the State a plot of 28,000 sq. meters in Beit Shemesh Industrial Zone for its new premises and plant.

 

In January 2005, subject signed a deal to sell its premises in Jerusalem, for a sum of US$ 2.9 million.

 

During March-May 2005, subject completed the move to its new 13,000 plant in Beit Shemesh, with total investments of NIS 68 million (including acquired land).

 

In August 2004, subject established a new subsidiary in Brazil, with an investment of US$ 200,000.

 

In October 2006, it was reported that subject will export sterilization devices to medical institutions in the USA, after winning several tenders in value of US$ 8-10 million.

 

Israel is considered one of the leading countries in the world in terms of investment in the Life Science and Biotechnology industry.

 

There are some 260 biotechnology companies operating in Israel as of 2015, 220 of which are Israeli, the rest are subsidiaries of foreign companies. The volume of investments in R&D in the biotechnology field is around US$ 400 million per annum, placing Israel 5th in the world in terms of investment in commercial R&D in biotechnology in respect of the GDP.

 

As of 2014, there are some 1,100 companies in the Life Science sector in Israel, of which 70% are in the medical devices fields, according to the Israel Export Institution estimation.

 

Export of medical devices rose by 11% in 2014 from 2013, and summed up to US$ 2 billion.

 

 

SUMMARY

 

Notwithstanding the lack of updated data from subject's officials, considered good for trade engagements.

 

Note: Since February 2013 Israel Post has started using a new area code method of 7 digits (the old method of 5 digits is no longer valid).

 

 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.63.50

UK Pound

1

Rs.99.17

Euro

1

Rs.69.39

 

INFORMATION DETAILS

 

Analysis Done by :

DIV

 

 

Report Prepared by :

NIT

 

 

RATING EXPLANATIONS

 

RATING

STATUS

PROPOSED CREDIT LINE

 

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

 

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

 

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

 

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

 

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

 

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

 

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

Credit not recommended

 

--

NB

New Business

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.